Background Clozapine is the most effective medication for the positive symptoms of treatment-refractory schizophrenia. Although clozapine use is associated with fewer admissions, less is known about the impact of clozapine cessation on hospitalisation. Aims The aims of this study were to investigate whether clozapine-reduced psychiatric inpatient admissions and bed days, and investigate patient factors associated with these changes from a sample of 1906 people commenced on clozapine. Methods All people commencing clozapine during an acute hospitalisation over a 10-year period in Queensland, Australia, were included in this retrospective cohort study. A mirror image design was used to compare psychiatric bed days and hospitalisations 2 years before and after clozapine treatment, and the impact of clozapine continuation or early cessation. Changes in psychiatric bed days and hospitalisations were analysed using linear regression, adjusting for the duration on clozapine, sex, age, indigenous status, country of origin and time to clozapine commencement. Results/outcomes There was a significant reduction in bed days (29.55 days vs 24.46 days, p < 0.001) and admissions (2.27 vs 1.87 < 0.001) associated with clozapine commencement. This remained significant among clozapine continuers, but not among those with early cessation. Longer duration on clozapine was associated with greater reductions in psychiatric bed days and admissions. Age, sex and time to clozapine commencement, indigeneity and country of origin did not impact outcomes. Conclusion/interpretation Longer clozapine therapy led to a greater reduction in psychiatric bed days and hospitalisations. Early cessation was associated with a return to pre-clozapine levels of bed days and admissions.
Introduction
Schizophrenia has a prevalence of seven per 1000 (Saha et al. 2005) , or whom one-third will have treatment-refractory schizophrenia (TRS) despite adequate sequential trials of two antipsychotics (Howes et al. 2017 ). For people with TRS, clozapine is the most effective medication for reducing positive symptoms (Siskind et al. 2016) , hospitalisations (Land et al. 2017 ) and all-cause mortality (Tiihonen et al. 2009; Wimberley et al. 2017) .
Although clozapine use has been steadily increasing in the past decade (Bachmann et al. 2017) , it remains underused. Barriers to use include lack of prescriber experience, clozapine's adverse events and mental health service organisational and funding structures (Verdoux et al. 2018) . A particular concern in Australia is that 3% of patients on clozapine develop myocarditis, a rate some 30 times higher than other countries (Robinson et al. 2017) . The reasons for this are unclear as this finding cannot be explained by greater use of echocardiography than elsewhere, as myocarditis usually occurs within the first 4 weeks of treatment and, therefore, would not be detected by routine echocardiography at 6-month follow-up or thereafter (Robinson et al. 2017) . As a result of these barriers, only one-third of Australians with TRS are offered clozapine (Forrester et al. 2015) . Of those that commenced on clozapine, 46% remain on clozapine at 5 years, while 27.3% are discontinued during the initial 18-week weekly monitoring phase (Forrester et al. 2015) . Very similar figures for cessation are seen in the UK (Legge et al. 2016) .
Clozapine use is associated with fewer admissions, notably a 26% reduction in proportion of people hospitalised, and a 34-day reduction in hospital bed days (Land et al. 2017) . However, less is known about the impact of clozapine cessation on hospitalisation. In a small British study (n = 102), cessation of clozapine led to a return to levels of hospital admissions that patients had experienced prior to the commencement of the therapy (Gee et al. 2016) .
Clozapine is associated with reductions in violence and offending (Bhavsar et al. 2018) , and as such is used in forensic and extended stay in mental health facilities (Stone-Brown et al. 2016) . Given the legal and psychosocial barriers to discharge from these facilities, clozapine is most likely to have an impact on acute inpatient hospital use, which is the single largest contributor to the direct cost of schizophrenia to mental health services (Knapp et al. 2004) .
Using a large database of all clozapine initiations in Queensland, Australia, over 10 years, we had the following two hypotheses:
1. Clozapine initiation will be associated with a reduction in acute psychiatric bed days and psychiatric admissions. 2. Longer duration on clozapine will be associated with greater reductions in acute psychiatric bed days and psychiatric admissions.
Methods

Study design
We followed the STROBE guidelines for reporting cohort studies (von Elm et al. 2007 ).
Data sources
A dataset of all people commenced on clozapine in Queensland from January 1, 2004, to December 31, 2013, was drawn from the Queensland state-wide iPharmacy dispensing data collection. Details on this dataset development are provided in our previous study (Forrester et al. 2015 
Data definitions
We included patients commenced on clozapine during an acute psychiatric hospitalisation, defined as being fewer than 180 days. An index hospitalisation was defined as the psychiatric hospitalisation, during which clozapine was first initiated. This study used a 'mirror image' design, around the index hospitalisation. The period of 24 months prior to the date of admission to the index hospitalisation was used as the pre-period mirror point, while a period of 24 months from the date of discharge from the index hospitalisation was used as the post-period mirror point. The index admission was excluded from both the pre-and post-mirror periods. All patients had 24 months of hospital admission data prior to index hospitalisation. Anyone with fewer than 24 months of follow-up time following discharge post clozapine admission was excluded from the dataset. We excluded patients who had more than 180 bed days in the 24 months before or after the mirror points. This was because the majority of these patients in this jurisdiction would be in forensic mental health facilities and would have barriers to discharge beyond mental state, including legal and psychosocial factors, which may lead to excess bed days unrelated to initiation of clozapine.
Data points
Data were extracted for the pre-and post-mirror periods on the number of psychiatric bed days and hospitalisations. For the primary outcomes of changes in psychiatric bed days and hospitalisations, the number in the 24 months after the postmirror point was subtracted from the number in the 24 months before the pre-mirror point. Data were also extracted on sex, age at the pre-mirror point, country of birth and indigenous status. The date of the first psychiatric hospitalisation since dataset inception (irrespective of whether clozapine was initiated during this hospitalisation) was recorded as a proxy marker for the time of the first diagnosis of a psychotic illness. The duration between this first admission date and the date of clozapine initiation was calculated as the duration of psychotic illness before clozapine initiation. For people commencing clozapine in 2004, this included up to 8 years of hospitalisation data prior to commencing clozapine. The first date of clozapine cessation, if one occurred during the dataset time period, was recorded. Cessation was divided into early cessation (within 18 weeks of initiation) and late cessation (between 18 weeks and 729 days of initiation). Those still on clozapine at 2 years were deemed continuers.
In Queensland, people commenced on clozapine are monitored weekly for the first 18 weeks after clozapine commencement, then 4-weekly thereafter (Galletly et al. 2016 ).
Statistical methods
Bed days and admissions in the 24 months before and after the mirror points were compared for the entire cohort, as well as early cessation, late cessation and continuation groups using t tests. We then calculated differences in the change in bed days and admissions between the three groups (early cessation, late cessation, continuation) using ANOVA with Bonferroni correction. The rates of readmissions between the three groups were compared using a chi-square test.
Finally, we conducted multiple linear regressions with the dependant variables as the change in bed days or hospitalisations between before and after the mirror points, and the following covariables: duration on clozapine, age at clozapine initiation, sex, indigenous status, country of birth and duration of psychotic illness before clozapine initiation. If any co-variates were significant, they were included in a multiple linear regression. Adjusted R 2 of the final model was calculated.
Results
1906 patients met inclusion criteria during the study time period. The mean age of the cohort was 35.65 years (SE 0.28), 69% were male and the mean duration of psychotic illness prior to commencing clozapine was 5.06 years (SE 0.10). The mean duration of hospitalisation prior to the mirror point was 29.55 days (SE 0.87). Demographics of the cohort are provided in Table 1 .
Bivariate analyses
The mean number of bed days fell significantly in the 24 months after commencing clozapine compared with the prior equivalent period in the entire cohort and continuation group, but not the early or late cessation groups (Table 2) . For the number of admissions in the 24 months before and after the mirror points, there was a statistically significant reduction for the entire cohort, late cessation and continuation groups but not the early cessation group (Table 2) . These findings translated into a mean reduction of 5.09 bed days (SE 1.11) and 0.41 admissions (SE 0 .11) from the 24 months before to the 24 months after the mirror points (SE 1.11) ( Table 3) . People who continued clozapine had 10.20 fewer bed days (SE 1.75) after the mirror point compared with before (Table 3) , a significantly greater reduction when compared with people with early cessations (0.34 more bed days, SE 1.90, p < 0.001) and late cessations (1.60 fewer bed days, SE 2.07, p = 0.006) ( Table 4 ). Neither those with early or late cessation had a significant reduction in bed days with there being no significant difference between the two groups ( Table 2) .
As regards the number of admissions, those who continued clozapine had 0.71 fewer occurrences of hospitalisations (SE 0.17), significantly less than those with early cessations (0.11 more hospitalisations, SE 0.19, p = 0.004) but not those with late cessations (0.45 fewer hospitalisations, SE 0.20, p = 1.00). The difference between early and late cessation was not significant. The combined F statistic was 5.10, 2 degrees of freedom, p = 0.006. The rate of readmission was highest for the early cessation group (59.6%), followed by the late cessation group (57.7%), with the continuation group having the lowest rate of readmission (45.5%) (p < 0.001, chi-square 33.467, degrees of freedom = 2).
Linear regression
For the change in bed days before and after the mirror points, both sex and duration on clozapine were significant in the individual linear regressions. All other variables had no effect. When these were both included in the final model, only increased duration on clozapine was significantly associated with a reduction in bed days (beta − 0.095, t − 4.182, p < 0.001, adjusted R 2 0.010) (Supplementary Table 1 ). Only increased duration on clozapine was significantly associated with a reduction in number of admissions before and after the mirror points (beta − 0.066, t − 2.895, p = 0.004, adjusted R 2 0.004) (Supplementary Table 2 ). 
Discussion
This large cohort study investigated the impact of clozapine commencement on subsequent psychiatric bed days and admissions. Clozapine led to a reduction in both total number of days spent in the hospital and in the number of admissions to hospital. Longer clozapine therapy was associated with greater reductions in bed days and admissions, whilst early cessation resulted in bed days and number of admissions returning to pre-commencement levels. However, gender, age, indigenous status, country of birth and duration of psychotic illness before clozapine initiation were not associated with either outcome. This suggests that commencing clozapine can still have a benefit on acute psychiatric bed days, irrespective of how late in the course of the illness it was started. Our finding that a longer duration on clozapine leads to greater reductions in bed days builds on the results of a recent meta-analysis which found clozapine to be associated with a reduction in psychiatric bed days and hospitalisations (Land et al. 2017 ). However, our study did not find any significant association between age and response to clozapine, in contrast to previous studies (Gee et al. 2016; Ucok et al. 2006) .
The study had a number of strengths, particularly its large and representative sample size and long follow-up period. Our study's within-subjects design helped to minimise the impact of individual-level confounders on the duration and number of inpatient admissions by effectively comparing the patient against themselves. Data on dispensing of clozapine were collected through a jurisdiction-wide pharmacy dispensing software system, which has been previously shown to be accurate (Forrester et al. 2015 ).
There were several limitations. Firstly, as with all mirror image studies, there is the risk that a reduction in bed days may be due to regression to the mean. Secondly, we did not have access to data on clinical acuity or psychosocial variables such as housing that may confound health service use. The use of inpatient admissions and hospital bed days as a substitute for clinical improvement in mental state may be imprecise. However, this may partly be accounted for with a mirror image design. Thirdly, we did not have coding for hospital type and patients in forensic or extended-stay facilities may have barriers to discharge over and above clinical acuity. This is why we excluded these patients from the dataset by using 6-month lengths of stay in hospital as a proxy, although we acknowledge this may be imprecise. Fourthly, we did not have records of pre-clozapine medication trials, and as such, the use of clozapine is only a proxy measure for treatment-refractory schizophrenia. Fifthly, the duration of psychotic illness prior to commencing clozapine was based on the assumption that the first psychiatric hospitalisation was the onset of psychotic illness and given the primary dataset only extended to 1996, we may have underestimated duration of illness. Finally, we were not able to include data on clozapine dose or levels to confirm whether or not trials of clozapine were likely to be therapeutic, or whether cessation was related to lack of efficacy or side effects. It is possible that early cessation may be due to adverse events, or late cessation due to inadequate response or blood testing burden.
In conclusion, we have shown that longer duration on clozapine is associated with a greater reduction in the number of psychiatric bed days and hospitalisations. However, this benefit is lost among those with early cessation of clozapine. The reduction in acute psychiatric bed use appears to be independent of the duration or severity of illness. Given the strong evidence for its role in treatment refractory schizophrenia (Land et al. 2017; Siskind et al. 2016) , clozapine remains underutilised. Strategies to improve access to clozapine include implementation of integrated clozapine clinics, simplification of blood monitoring, education for prescribers and contact with experienced prescribers (Verdoux et al. 2018 ). Further research is required to clarify reasons for early and late cessation of clozapine.
Compliance with ethical standards Ethics approval was granted by the Metro South Human Research Ethics Committee HREC/15/QPAH/400. One-way ANOVA 1 F = 9.34, 2 degrees of freedom, p < 0.001 2 F = 5.10, 2 degrees of freedom, p = 0.006
